403 related articles for article (PubMed ID: 8708714)
1. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.
Chang A; Yeap B; Davis T; Blum R; Hahn R; Khanna O; Fisher H; Rosenthal J; Witte R; Schinella R; Trump D
J Clin Oncol; 1996 Aug; 14(8):2250-7. PubMed ID: 8708714
[TBL] [Abstract][Full Text] [Related]
2. The role of diethylstilbestrol in the treatment of prostate cancer.
Malkowicz SB
Urology; 2001 Aug; 58(2 Suppl 1):108-13. PubMed ID: 11502463
[TBL] [Abstract][Full Text] [Related]
3. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
Soloway MS; Schellhammer P; Sharifi R; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Eur Urol; 1996; 29 Suppl 2():105-9. PubMed ID: 8717471
[TBL] [Abstract][Full Text] [Related]
4. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
[TBL] [Abstract][Full Text] [Related]
5. Hormone therapy of prostatic bone metastases.
Huben RP
Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
[TBL] [Abstract][Full Text] [Related]
6. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
[TBL] [Abstract][Full Text] [Related]
7. Comparison of goserelin and leuprolide in combined androgen blockade therapy.
Sarosdy MF; Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Vogelzang NJ; Chodak GW; Klein EA; Schellenger JJ; Kolvenbag GJ
Urology; 1998 Jul; 52(1):82-8. PubMed ID: 9671875
[TBL] [Abstract][Full Text] [Related]
8. [Recurrence of cancer of the prostate after initial treatment with diethylstilbestrol (DES) in a homogeneous series of 175 cases].
Reziciner S
Ann Urol (Paris); 1997; 31(4):213-24. PubMed ID: 9412346
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment versus LHRH alone in advanced prostatic cancer.
Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Schellenger JJ; Kolvenbag GJ
Urology; 1997 Sep; 50(3):330-6. PubMed ID: 9301693
[TBL] [Abstract][Full Text] [Related]
11. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.
Hedlund PO; Henriksson P
Urology; 2000 Mar; 55(3):328-33. PubMed ID: 10699602
[TBL] [Abstract][Full Text] [Related]
12. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
[TBL] [Abstract][Full Text] [Related]
13. The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer.
Pitts WR
BJU Int; 2004 May; 93(7):1119-20. PubMed ID: 15142186
[No Abstract] [Full Text] [Related]
14. Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer.
Burns-Cox N; Basketter V; Higgins B; Holmes S
Int J Urol; 2002 Aug; 9(8):431-4. PubMed ID: 12225339
[TBL] [Abstract][Full Text] [Related]
15. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA
N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805
[TBL] [Abstract][Full Text] [Related]
16. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.
Moinpour CM; Savage MJ; Troxel A; Lovato LC; Eisenberger M; Veith RW; Higgins B; Skeel R; Yee M; Blumenstein BA; Crawford ED; Meyskens FL
J Natl Cancer Inst; 1998 Oct; 90(20):1537-44. PubMed ID: 9790546
[TBL] [Abstract][Full Text] [Related]
17. Flutamide therapy for carcinoma of the prostate.
Airhart RA; Barnett TF; Sullivan JW; Levine RL; Schlegel JU
South Med J; 1978 Jul; 71(7):798-801. PubMed ID: 78529
[TBL] [Abstract][Full Text] [Related]
18. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
Scherr DS; Pitts WR
J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
[TBL] [Abstract][Full Text] [Related]
19. Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
Leuprolide Study Group
N Engl J Med; 1984 Nov; 311(20):1281-6. PubMed ID: 6436700
[TBL] [Abstract][Full Text] [Related]
20. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Chen Y; Kolvenbag GJ
Cancer; 1996 Nov; 78(10):2164-9. PubMed ID: 8918410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
